Vilazodone 20 mg Tablets are a generic form of Viibryd, containing vilazodone hydrochloride as the active ingredient. Vilazodone is an oral antidepressant used to treat major depressive disorder (MDD) in adults where approved. Major depressive disorder is a mental health condition that can affect mood, interest in activities, sleep, appetite, concentration and everyday functioning.
Vilazodone belongs to a pharmacological class that combines serotonin reuptake inhibition with partial agonist activity at 5-HT1A serotonin receptors. These actions affect serotonergic neurotransmission, which is involved in mood regulation.
The 20 mg tablet is used within a prescribed treatment regimen. The appropriate dose, treatment schedule and monitoring plan depend on the patient’s clinical circumstances and the prescribing information applicable in the relevant country.
| Product attribute | Details |
|---|---|
| Product name | Vilazodone 20 mg Tablets |
| Generic relationship | Generic form of Viibryd |
| Active ingredient | Vilazodone hydrochloride |
| Strength | 20 mg per tablet |
| Dosage form | Oral tablet |
| Therapeutic class | Serotonin reuptake inhibitor and 5-HT1A receptor partial agonist |
| Main treatment area | Major depressive disorder in adults, where approved |
| Route of administration | Oral |
| Administration with food | Take with food, according to product instructions |
| Reference brand | Viibryd |
| Product type | Generic prescription medicine |
| Pack size | Depends on the supplied product |
| Manufacturer | Depends on the specific product supplied |
Vilazodone is used to treat adults with major depressive disorder under the US prescribing information. The exact approved indication, age requirements and product availability depend on national authorization and the specific product label.
Major depressive disorder can involve persistent low mood, loss of interest or pleasure, changes in sleep or appetite, reduced energy, difficulty concentrating and changes in everyday functioning. Vilazodone is a prescription treatment option for eligible adults following clinical assessment.
Treatment decisions take account of symptom severity, previous treatment response, medical history, other medicines and individual safety considerations. Vilazodone is not an immediate-relief medicine, and improvement may take several weeks.
A prescriber may review response and tolerability during treatment and adjust the regimen when appropriate. Continued follow-up is important to evaluate clinical benefit, adverse effects and the need for ongoing treatment.
Vilazodone inhibits the serotonin transporter, reducing serotonin reuptake, and acts as a partial agonist at 5-HT1A serotonin receptors. These actions influence serotonergic signalling in the central nervous system.
The exact contribution of each pharmacological action to vilazodone’s antidepressant effect is not fully established. Its clinical effect develops over time, and response varies between individuals.
Vilazodone is a treatment for depression rather than a cure. Treatment planning and monitoring should be guided by a qualified healthcare professional.
The appropriate dose depends on the prescription, patient characteristics, tolerability and the locally approved product information.
Under US prescribing information for adults with major depressive disorder, treatment starts at 10 mg orally once daily with food for seven days, followed by 20 mg once daily with food. Depending on response and tolerability, the dose may be increased to 40 mg once daily after at least seven days between dose increases.
Vilazodone should be taken with food because food affects its absorption.
The regimen above reflects US prescribing information and is not an individualized prescription. Follow the current local product label and the treating healthcare professional’s directions.
Before vilazodone treatment begins, the prescriber should review the patient’s medical history, current medicines and relevant risk factors. Assessments may include:
The extent of monitoring depends on individual circumstances and the applicable product information.
Vilazodone can cause side effects, and their severity varies between patients. Reported adverse effects include:
Important less common or serious risks include serotonin syndrome, increased bleeding, mania or hypomania, seizures, hyponatremia and discontinuation symptoms.
Seek urgent medical attention for suspected serotonin syndrome, a seizure, a severe allergic reaction or an immediate risk of self-harm. Contact the prescriber about persistent or troublesome adverse effects.
Antidepressants carry a warning about an increased risk of suicidal thoughts and behaviors in children, adolescents and young adults. Monitor for worsening depression, unusual behavioral changes, severe agitation or emerging suicidal thoughts, particularly when treatment starts or the dose changes. Imminent danger requires emergency assistance.
Vilazodone can cause serotonin syndrome, particularly when combined with other serotonergic medicines. Warning symptoms may include agitation, confusion, sweating, fever, rapid heartbeat, tremor, muscle rigidity or impaired coordination. Suspected serotonin syndrome requires urgent medical assessment.
Vilazodone may increase bleeding risk, particularly when taken with aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), antiplatelet medicines or anticoagulants. Inform the prescriber about all medicines and supplements.
Patients should be assessed for a personal or family history of bipolar disorder before starting treatment. Antidepressants may trigger mania or hypomania in susceptible individuals.
Patients with a seizure disorder or factors that increase seizure risk require clinical assessment before treatment. Report any seizure history to the prescriber.
Antidepressants can be associated with hyponatremia, or low blood sodium. Older adults, people taking diuretics and individuals who are volume-depleted may have an increased risk. New confusion, severe weakness, marked unsteadiness or severe headache should be medically assessed.
Discuss pregnancy, plans for pregnancy and breastfeeding with the prescriber before starting or changing treatment. The decision should consider the potential benefits of treatment, the risks of untreated depression and the available evidence. Do not stop vilazodone without professional advice.
Stopping vilazodone abruptly may cause discontinuation symptoms. If treatment is to be stopped, the prescriber may recommend a gradual dose reduction and follow-up.
Under US prescribing information, vilazodone is contraindicated with monoamine oxidase inhibitors (MAOIs) and during the specified period after MAOI treatment because of the risk of serotonin syndrome.
Potential interactions include:
The precise contraindications, washout periods and interaction instructions should be checked against the current product label and the patient’s medication list.
Viibryd is the reference brand containing vilazodone. Generic vilazodone tablets contain the same active ingredient and corresponding strength when authorized as a generic equivalent.
The generic product may differ from the reference brand in manufacturer, tablet appearance, packaging and inactive ingredients. The actual product label identifies the manufacturer, formulation, pack size and applicable market authorization.
Vilazodone is one of several medicines used to treat depression. Other antidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs) and other medicines with different pharmacological mechanisms.
These treatments are not automatically interchangeable. Choice of treatment depends on the diagnosis, symptoms, previous treatment response, other medical conditions, potential interactions, adverse-effect profiles and prescribing guidance.
Vilazodone is used to treat major depressive disorder in adults where the indication is approved. A healthcare professional determines whether it is suitable for an individual patient.
Yes. Vilazodone is the active ingredient in Viibryd, and generic vilazodone tablet products are available in some markets.
The active ingredient is vilazodone, supplied as vilazodone hydrochloride in tablet formulations.
Authorized generic products contain the same active ingredient and corresponding strength as the reference product. Manufacturer, packaging, tablet appearance and inactive ingredients may differ.
Vilazodone inhibits serotonin reuptake and acts as a partial agonist at 5-HT1A receptors. It affects serotonergic neurotransmission involved in mood regulation.
Under US prescribing information, vilazodone is taken orally once daily with food, following a prescribed titration regimen. Follow the applicable product instructions and prescription.
Yes. Vilazodone should be taken with food because food affects its absorption.
Commonly reported effects include diarrhea, nausea, vomiting and insomnia. Other adverse effects may occur.
Combining vilazodone with other serotonergic medicines can increase the risk of serotonin syndrome. A healthcare professional should review all medicines before treatment is started or changed.
Abrupt discontinuation can cause symptoms. A gradual reduction may be recommended under the prescriber’s supervision.
Vilazodone is a prescription medicine in the United States. Prescription requirements in other countries depend on local regulations.
The price varies according to manufacturer, pack size, supplier, country and applicable prescription and dispensing requirements. Use the actual product listing for current price information.
Generic vilazodone is available in some markets. Availability, approved products and regulatory status vary by country.
This product information is provided for general educational and product-description purposes. Vilazodone is a prescription medicine that requires appropriate clinical assessment. The current product label and advice from a qualified healthcare professional determine suitability, dosage, contraindications, interactions and monitoring requirements.
Orders ship from our India Head Office within 1–2 business days of confirmation. We include full customs documentation — HS codes, certificates of origin, and pharmaceutical export permits.
Estimated delivery: 3–7 business days to UK. 7–10 business days to UAE, Saudi Arabia and Gulf countries. 10–15 days for USA and Asian countries.
All packages arrive in plain, unmarked brown boxes. No pharmacy name or medication details on the outside.
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.